Information for Our Community

Whether you are part of our community or are interested in joining us, we welcome you to Washington University School of Medicine.

close  


Visit the News Hub

Study IDs why some TB bacteria prove deadly

Single mutation protects TB bacteria from antibiotics, immune assault

by Tamara BhandariSeptember 17, 2018

Matt Miller

People who fall sick with drug-resistant tuberculosis (TB) face daunting odds. Only about two in three survive the illness, unlike people with drug-sensitive TB, of whom more than 90 percent survive.

Part of the reason drug-resistant TB is so lethal is because some antibiotics of first choice don’t kill the TB bacteria, forcing doctors to treat the infection with second-line medications that are often more toxic and less effective.

But the TB bacteria also may be undermining the body’s ability to defend itself. Researchers at Washington University School of Medicine in St. Louis have found that the same mutation that makes TB bacteria withstand a first-line drug also elicits a different – and probably weaker – immune response in mice.

“As the bacteria become drug resistant, they change physiologically and trick the immune system to behave differently,” said Shabaana A. Khader, PhD, an associate professor of molecular microbiology and the study’s senior author. “If we’re going to fight TB bacteria effectively, we’re going to have to understand what the drug-resistant bacteria are doing to the immune system to elicit protection.”

The findings are published Sept. 17 in Nature Microbiology.

There have been hints for years that drug-resistant bacteria might interact with the body differently than drug-sensitive strains. Anecdotal reports suggest that resistant TB bacteria cause more damage to the lungs and spread more widely through the body.

Khader, working with graduate student and first author Nicole Howard and colleagues, analyzed the immune response in mice infected with Mycobacterium tuberculosis, the bacteria that cause TB. They compared a strain that is resistant to all first- and many second-line antibiotics with a drug-sensitive strain of TB.

The mice’s immune systems battled the sensitive bacteria by releasing a powerful immune molecule known as IL-1 beta and ramping up the ability of their immune cells to burn sugar. Both actions are crucial for an effective immune assault on the TB bacteria.

But when infected with the drug-resistant strain, the mice failed to pull out the big guns. Their immune cells did not burn more sugar, and they failed to produce much IL-1 beta. Instead, they released a different immune molecule, IFN beta, which is associated with a feeble and sometimes detrimental immune response to TB.

“People always thought that development of drug resistance just meant that there’s a change in how bacteria respond to antibiotics,” Khader said. “But this shows that the whole immune environment is changing in ways that we haven’t been fully aware of.”

To find out why drug-resistant bacteria elicit a different immune response, the researchers scanned the whole genomes of several drug-resistant strains. They found that a change of one letter in the genetic code gave bacteria the ability to withstand rifampicin, an important first-line antibiotic, and also altered the immune response.

Treating TB is a long, drawn-out process. The bacteria grow slowly and are wrapped in a protective shell, so it takes a combination of four antibiotics given repeatedly over six months to eradicate them. Boosting the immune response would be like sending in fresh troops to a protracted battle – it could put an end to the fight, quickly and decisively. Clinical trials are already underway to find out whether immune-enhancing drugs combined with antibiotics improves outcomes for people with TB. But because of the inherent dangers of working with drug-resistant bacteria, nearly all research into strengthening the immune response has been conducted using drug-sensitive strains.

“If you’re going to do host-directed therapeutics, we need to know what immune pathways to target,” Khader said. “And these pathways may turn out to be different for drug-sensitive and drug-resistant TB.”

Howard and Khader’s findings suggest that the people most in need of better therapeutics – those infected with drug-resistant strains – may not benefit from immune enhancers that are designed based on drug-sensitive bacteria.

“We don’t know enough about the differences between resistant and sensitive TB to be confident that the therapeutics and vaccines we’re designing are going to work,” Khader said. “We’re going to have to do those studies.”

Howard NC, Marin ND, Ahmed M, Rosa BA, Martin J, Bambouskova M, Sergushichev A, Loginicheva E, Kurepina N, Rangel-Moreno J, Chen L, Kreiswirth B, Klein RS, Balada-Llasat JM, Torrelles JB, Amarasinghe GK, Mitreva M, Artyomov MN, Hsu FF, Mathema B, Khader SA. Mycobacterium tuberculosis carrying a rifampicin drug resistance mutation reprograms macrophage metabolism through cell wall lipid changes. Nature Microbiology. Sept. 17, 2018.

This study was supported by the National Institutes of Health (NIH), grant numbers HL105427, AI123780, AI111914 and U19 AI91036; the National Heart, Lung, and Blood Institute, grant numbers T32 HL007317-37; the Ministry of Education and Science of the Russian Federation, project number 2.3300.2017/4.6; and the Department of Medicine at the University of Rochester. The protein identifications and LC-MS analyses were generated at the Washington University Proteomics Shared Resource, which is supported by the Washington University Institute of Clinical and Translational Sciences, grant number NCATS UL1 TR000448; the WU Mass Spectrometry Research Resource, which is supported by the National Institute of General Medical Sciences, grant numbers P41 GM103422, P60-DK-20579, P30-DK56341; and the Siteman Comprehensive Cancer Center, which is supported by the National Cancer Institute, grant numbers P30 CA091842.

Washington University School of Medicine’s 1,300 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

Tamara covers infectious diseases, molecular microbiology, neurology, neuroscience, surgery, the Institute for Informatics, the Division of Physician-Scientists and the MSTP program. She holds a double bachelor's degree in molecular biophysics & biochemistry and in sociology from Yale University, a master's in public health from the University of California, Berkeley, and a PhD in biomedical science from the University of California, San Diego. She joined WashU Medicine Marketing & Communications in 2016. She has received three Robert G. Fenley writing awards from the American Association of Medical Colleges: a bronze in 2020 for "Mind’s quality control center found in long-ignored brain area," a silver in 2022 for "Mice with hallucination-like behaviors reveal insight into psychotic illness," and a bronze in 2023 for "Race of people given Alzheimer’s blood tests may affect interpretation of results." Since January of 2024, Tamara has been writing under the name Tamara Schneider.